id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2025-E-0500-0006,FDA,FDA-2025-E-0500,Determination of Regulatory Review Period for Purposes of Patent Extension; TRYNGOLZA,Notice,Determinations,2026-02-26T05:00:00Z,2026,2,2026-02-26T05:00:00Z,2026-04-28T03:59:59Z,2026-02-26T20:57:25Z,2026-03850,1,0,09000064b91deac5
FDA-2025-E-0500-0005,FDA,FDA-2025-E-0500,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2025-12-02T05:00:00Z,2025,12,2025-12-02T05:00:00Z,,2025-12-03T02:25:19Z,,0,0,09000064b90a9fe0
FDA-2025-E-0500-0004,FDA,FDA-2025-E-0500,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2025-11-05T05:00:00Z,2025,11,2025-11-05T05:00:00Z,,2025-11-05T22:29:58Z,,0,0,09000064b906967b
FDA-2025-E-0500-0003,FDA,FDA-2025-E-0500,Letter from FDA CDER to U.S. Patent and Trademark Office,Other,Letter(s),2025-10-10T04:00:00Z,2025,10,2025-10-10T04:00:00Z,,2025-11-05T18:09:50Z,,0,0,09000064b9006815
FDA-2025-E-0500-0001,FDA,FDA-2025-E-0500,Letter from U.S. Patent and Trademark Office to FDA CDER,Other,Letter(s),2025-02-28T05:00:00Z,2025,2,2025-02-28T05:00:00Z,,2025-02-28T18:37:35Z,,0,0,09000064869951bd
FDA-2025-E-0500-0002,FDA,FDA-2025-E-0500,"Patent Extension Application from Cooley LLP (on behalf of Ionis Pharmaceuticals, Inc.)",Other,Application,2025-02-28T05:00:00Z,2025,2,2025-02-28T05:00:00Z,,2025-02-28T18:40:01Z,,0,0,09000064869951be